Showing 3641-3650 of 4164 results for "".
- Zeiss Introduces New Solution Enhancements for Procedure Workflows at ESCRS and Euretinahttps://modernod.com/news/zeiss-introduces-new-solution-enhancements-for-procedure-workflows-at-escrs-and-euretina/2478352/At the ESCRS virtual conference, Zeiss is presenting new solution enhancements aimed at helping doctors maximize clinical efficiency and improve patient care—from assessment, diagnosis, to treatment. Zeiss says the la
- US Eye Network Expands into Southeastern US through Partnership with Carolina Eyecare Physicianshttps://modernod.com/news/us-eye-network-expands-into-southeastern-us-through-partnership-with-carolina-eyecare-physicians/2478319/Carolina Eyecare Physicians has joined the expanding US Eye network. With the addition of Carolina Eyecare Physicians, US Eye, a physician-led network of practices, will operate 24 clinics and 3 surgery centers. <
- Liminal BioSciences Provides Update on Progress on BLA for Ryplazim (Plasminogen)https://modernod.com/news/liminal-biosciences-provides-update-on-progress-on-bla-for-ryplazim-plasminogen/2478301/Liminal BioSciences announced that the FDA acknowledged receipt of the resubmission of the Biologic License Application (BLA) for Ryplazim (plasminogen) for the treatment of clinical signs and symptoms associated with congenital plasminogen deficiency (C-PLGD) in pediatrics and adults. The
- AGTC Formalizes Patient Advisory Council to Provide Insights and Guidance for Pipeline Therapieshttps://modernod.com/news/agtc-formalizes-patient-advisory-council-to-provide-insights-and-guidance-for-pipeline-therapies/2478156/Applied Genetic Technologies Corporation (AGTC), announced the formation of a Patient Advisory Council to build on its focus of incorporating the patient and caregiver voice into the company’s culture and clinical and preclinical programs. Engagement with pa
- Russia’s Approval of Virus Vaccine Greeted With Some Alarmhttps://modernod.com/news/russias-approval-of-virus-vaccine-greeted-with-some-alarm/2478146/Russia on Tuesday became the first country to approve a coronavirus vaccine for use in tens of thousands of its citizens despite international skepticism about injections that have not completed clinical trials and were studied in only dozens of pe
- Aurinia Prices $200 Million Public Offering of Common Shareshttps://modernod.com/news/aurinia-prices-200-million-public-offering-of-common-shares/2478066/Aurinia Pharmaceuticals, a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the pricing of its underwritten public offering of 13,333,334 common shares. The company is currently developing the investig
- Appeals Court Rules HHS Has Authority to Implement Site Neutral Payments, Dealing Blow to Hospitalshttps://modernod.com/news/appeals-court-rules-hhs-has-authority-to-implement-site-neutral-payments-dealing-blow-to-hospitals/2478041/A federal appeals court ruled Health and Human Services has the authority to cut Medicare payments to off-campus clinics to bring them in line with independent physician practices, reversing a lower court’s decision, according to a FierceHealthcare
- Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Programhttps://modernod.com/news/aldeyra-therapeutics-receives-orphan-medicinal-product-designation-from-the-european-commission-for-adx-2191-retinal-disease-program/2477898/Aldeyra Therapeutics announced that ADX-2191 has been designated an orphan medicinal product by the European Commission for the treatment of retinal detachment. ADX-2191 is an investigational therapy in clinical development in the U.S. for the prevention of proliferative vitreoretinopathy (PVR),
- Diabetic Retinopathy Approaches Refined by New Trial Resultshttps://modernod.com/news/diabetic-retinopathy-approaches-refined-by-new-trial-results/2477686/Data from clinical trials are prompting leading diabetic retinopathy specialists to change their approach to treatment, according to a Medscape report. The Protocol studies conducted by the DRCR Retina Network, which is funded by t
- Sanofi/Regeneron and Roche Report Mixed Results for Potential COVID-19 Treatmentshttps://modernod.com/news/sanofi-regeneron-and-roche-report-mixed-results-for-potential-covid-19-treatments/2477661/Sanofi and Regeneron Pharmaceuticals said that preliminary results from the phase 2 portion of an ongoing study showed that the IL-6 receptor antibody Kevzara (sarilumab) had “no notable benefit” on clinical outcomes v